Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 791-792

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Anti atherosclerotic medications; Cardiovascular disease; Older; Single pill; Younger

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; KIDNEY FUNCTION; LETTER; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATIENT COMPLIANCE; RISK REDUCTION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

AGE FACTORS; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG COMBINATIONS; FATTY LIVER; HEPTANOIC ACIDS; HUMANS; METABOLIC DISEASES; PATIENT COMPLIANCE; PYRROLES; RISK; RISK REDUCTION BEHAVIOR;

EID: 84880292967     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.805536     Document Type: Letter

References (11)

1. Kim JH, Zamorano J, Erdine S, et al; on behalf of the CRUCIAL Investigators. Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (<65 years) and older (>65 years) patients in the CRUCIAL trial. Curr Med Res Opin 2013;29:1-11
2. Athyros VG, Katsiki N, Tziomalos K, et al.; for the GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE Study. Arch Med Sci 2013 [in press]
3. Athyros VG, Tziomalos K, Gossios TD, et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 2010;376:1916-22
4. Athyros VG, Ganotakis E, Kolovou GD, et al; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effesct in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011;9:647-57
5. Athyros VG, Karagiannis A, Ganotakis ES, et al; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
6. Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 2001;155:263-4
7. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
8. Katsiki N, Athyros VG, Karagiannis A. Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assessment 2013 [in press]
9. Kjeldsen SE, Messerli FH, Chiang CE, et al. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin 2012;28:1685-97
10. Levin P, Wei W, Wang L, et al. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012;28:439-46
11. Kaku K, Enya K, Sugiura K, et al. Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. Curr Med Res Opin 2011;27(Suppl 3):73-84